157 related articles for article (PubMed ID: 34311790)
21. Synthetic cannabinoid receptor agonists are monoamine oxidase-A selective inhibitors.
Hindson SA; Andrews RC; Danson MJ; van der Kamp MW; Manley AE; Sutcliffe OB; Haines TSF; Freeman TP; Scott J; Husbands SM; Blagbrough IS; Anderson JLR; Carbery DR; Pudney CR
FEBS J; 2023 Jun; 290(12):3243-3257. PubMed ID: 36708234
[TBL] [Abstract][Full Text] [Related]
22. Synthetic cannabis: adverse events reported to the New Zealand Pharmacovigilance Centre.
Robson H; Braund R; Glass M; Ashton J; Tatley M
Clin Toxicol (Phila); 2021 Jun; 59(6):472-479. PubMed ID: 33156704
[TBL] [Abstract][Full Text] [Related]
23. Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists.
Sachdev S; Banister SD; Santiago M; Bladen C; Kassiou M; Connor M
Pharmacol Res Perspect; 2020 Apr; 8(2):e00566. PubMed ID: 32101383
[TBL] [Abstract][Full Text] [Related]
24. Development of Cross-Reactive Antibodies for the Identification and Treatment of Synthetic Cannabinoid Receptor Agonist Toxicity.
Worob A; Wenthur CJ
Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016144
[TBL] [Abstract][Full Text] [Related]
25. Involuntary MDMB-4en-PINACA intoxications following cannabis consumption: clinical and analytical findings.
Goncalves R; Labadie M; Chouraqui S; Peyré A; Castaing N; Daveluy A; Molimard M
Clin Toxicol (Phila); 2022 Apr; 60(4):458-463. PubMed ID: 34850659
[TBL] [Abstract][Full Text] [Related]
26. Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015.
Cordeiro SK; Daro RC; Seung H; Klein-Schwartz W; Kim HK
Addiction; 2018 Oct; 113(10):1850-1861. PubMed ID: 29806885
[TBL] [Abstract][Full Text] [Related]
27. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution.
Banister SD; Connor M
Handb Exp Pharmacol; 2018; 252():191-226. PubMed ID: 30105473
[TBL] [Abstract][Full Text] [Related]
28. [Synthetic Cannabinoid Receptor Agonist-Associated Psychotic Disorder: A Case Report].
Sönmez İ; Köşger F
Turk Psikiyatri Derg; 2016; 27(1):63-6. PubMed ID: 27369687
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs.
Gioé-Gallo C; Ortigueira S; Brea J; Raïch I; Azuaje J; Paleo MR; Majellaro M; Loza MI; Salas CO; García-Mera X; Navarro G; Sotelo E
Biomed Pharmacother; 2023 Aug; 164():114934. PubMed ID: 37236027
[TBL] [Abstract][Full Text] [Related]
30. New psychoactive substance use as a survival strategy in rural marginalised communities in Hungary.
Csák R; Szécsi J; Kassai S; Márványkövi F; Rácz J
Int J Drug Policy; 2020 Nov; 85():102639. PubMed ID: 31911024
[TBL] [Abstract][Full Text] [Related]
31. Shape matters: The application of activity-based in vitro bioassays and chiral profiling to the pharmacological evaluation of synthetic cannabinoid receptor agonists in drug-infused papers seized in prisons.
Antonides LH; Cannaert A; Norman C; NicDáeid N; Sutcliffe OB; Stove CP; McKenzie C
Drug Test Anal; 2021 Mar; 13(3):628-643. PubMed ID: 33161649
[TBL] [Abstract][Full Text] [Related]
32. Detection and quantitation of synthetic cannabinoid receptor agonists in infused papers from prisons in a constantly evolving illicit market.
Norman C; Walker G; McKirdy B; McDonald C; Fletcher D; Antonides LH; Sutcliffe OB; Nic Daéid N; McKenzie C
Drug Test Anal; 2020 Apr; 12(4):538-554. PubMed ID: 31944624
[TBL] [Abstract][Full Text] [Related]
33. Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11.
Kevin RC; Cairns EA; Boyd R; Arnold JC; Bowen MT; McGregor IS; Banister SD
Front Psychiatry; 2022; 13():1048836. PubMed ID: 36590635
[TBL] [Abstract][Full Text] [Related]
34. Narrative Review of the Pharmacodynamics, Pharmacokinetics, and Toxicities of Illicit Synthetic Cannabinoid Receptor Agonists.
Lea Houston M; Morgan J; Kelso C
Mini Rev Med Chem; 2024; 24(1):92-109. PubMed ID: 37190813
[TBL] [Abstract][Full Text] [Related]
35. The impact of legislation on acute synthetic cannabinoid harms resulting in ambulance attendance.
Grigg J; Killian JJ; Matthews S; Scott D; Arunogiri S; Manning V; Taylor DA; Crossin R; Smith K; Lubman DI
Int J Drug Policy; 2020 Apr; 79():102720. PubMed ID: 32279004
[TBL] [Abstract][Full Text] [Related]
36. An Internet Snapshot Survey Assessing the sale of Synthetic Cannabinoid Receptor Agonists for use with Electronic Vaping Devices.
Gould A; Dargan PI; Wood DM
J Med Toxicol; 2024 Jun; ():. PubMed ID: 38839732
[TBL] [Abstract][Full Text] [Related]
37. Synthetic cannabinoid use in an acute psychiatric inpatient unit.
Clancy RV; Hodgson RC; Kendurkar A; Terry MA; Dadd L; Clancy DM; Ryan K; Hatzistylis M; Tinman BG
Int J Ment Health Nurs; 2018 Apr; 27(2):600-607. PubMed ID: 28503792
[TBL] [Abstract][Full Text] [Related]
38. Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011-2014.
Palamar JJ; Su MK; Hoffman RS
Am J Drug Alcohol Abuse; 2016; 42(1):39-47. PubMed ID: 26678258
[TBL] [Abstract][Full Text] [Related]
39. Cluster of Acute Toxicity from Ingestion of Synthetic Cannabinoid-Laced Brownies.
Obafemi AI; Kleinschmidt K; Goto C; Fout D
J Med Toxicol; 2015 Dec; 11(4):426-9. PubMed ID: 25967137
[TBL] [Abstract][Full Text] [Related]
40. Trends in hospital presentations following analytically confirmed synthetic cannabinoid receptor agonist exposure before and after implementation of the 2016 UK Psychoactive Substances Act.
Craft S; Dunn M; Vidler D; Officer J; Blagbrough IS; Pudney CR; Henderson G; Abouzeid A; Dargan PI; Eddleston M; Cooper J; Hill SL; Roper C; Freeman TP; Thomas SHL
Addiction; 2022 Nov; 117(11):2899-2906. PubMed ID: 35665553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
